SCHEMBL23345535

SCHEMBL23345535

O=C1c2ccccc2-c2cc(Nc3nc(Cl)nc4c3ncn4C3OC(CNP(=O)(O)CP(=O)(O)O)C(O)C3O)ccc21

nearest known ligand 0.57

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ NT5E P21589 18/20 0.54
▸ ADORA3 P0DMS8 1/20 0.49
▸ ADORA2A P29274 1/20 0.49
▸ ADORA1 P30542 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23345533 1.00 NT5E (0.54) NT5EADORA3ADORA2AADORA1
SCHEMBL27043383 0.91 NT5E (0.52) NT5EADORA3ADORA2AADORA1
SCHEMBL23345867 0.91 NT5E (0.52) NT5EADORA3ADORA2AADORA1
SCHEMBL23345863 0.91 NT5E (0.52) NT5EADORA3ADORA2AADORA1
SCHEMBL26283159 0.90 NT5E (0.52) NT5EADORA3
SCHEMBL23345846 0.90 NT5E (0.52) NT5EADORA3
SCHEMBL23345834 0.90 NT5E (0.52) NT5EADORA3
SCHEMBL23345697 0.90 NT5E (0.57) NT5EADORA3ADORA2AADORA1
SCHEMBL23345701 0.90 NT5E (0.57) NT5EADORA3ADORA2AADORA1
SCHEMBL22856816 0.90 NT5E (0.68) NT5E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240024346-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2024-01-25 — — US disclosed
US-20230295213-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2023-09-21 — — US disclosed
US-11530234-B2 CD73 inhibitors and pharmaceutical uses thereof Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2022-12-20 — — US disclosed
US-20210139526-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF RISEN (SUZHOU) PHARMA TECH Co.,Ltd. (CN) 2021-05-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295213-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF ENTPD5, NT5E, ENTPD1 NT5E 2/4885ADORA3 34/4885ADORA2A 17/4885
US-20240024346-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF ENTPD5, NT5E, ENTPD1 NT5E 2/4885ADORA3 34/4885ADORA2A 17/4885
US-11530234-B2 CD73 inhibitors and pharmaceutical uses thereof ENTPD5, ENTPD1, NT5E NT5E 3/4885ADORA3 35/4885ADORA2A 18/4885
US-20210139526-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF ENTPD5, ENTPD1, NT5E NT5E 3/4885ADORA3 35/4885ADORA2A 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback